Patients with membranous nephropathy can have circulating autoantibodies against membrane-bound (phospholipase A2 receptor 1 [PLA2R1] and thrombospondin type-1 domain containing 7A [THSD7A]) and intracellular (aldose reductase, SOD2, and α-enolase) podocyte autoantigens. We studied their combined association with clinical outcomes.
Multi-Autoantibody Signature and Clinical Outcome in Membranous Nephropathy
Scolari, Francesco;
2020-01-01
Abstract
Patients with membranous nephropathy can have circulating autoantibodies against membrane-bound (phospholipase A2 receptor 1 [PLA2R1] and thrombospondin type-1 domain containing 7A [THSD7A]) and intracellular (aldose reductase, SOD2, and α-enolase) podocyte autoantigens. We studied their combined association with clinical outcomes.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
autoantibody.pdf
solo utenti autorizzati
Tipologia:
Full Text
Licenza:
PUBBLICO - Creative Commons 2.1
Dimensione
5.68 MB
Formato
Adobe PDF
|
5.68 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
